Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical picture: nail changes secondary to docetaxel.
Wasner G, Hilpert F, Baron R, Pfisterer J. Wasner G, et al. Among authors: hilpert f. Lancet. 2001 Mar 24;357(9260):910. doi: 10.1016/s0140-6736(00)04210-0. Lancet. 2001. PMID: 11289346 No abstract available.
State-of-the-art first-line treatment of ovarian cancer.
Pfisterer J, Hilpert F, Du Bois A, Meier W, Wagner U. Pfisterer J, et al. Among authors: hilpert f. Onkologie. 2003 Oct;26(5):446-50. doi: 10.1159/000072977. Onkologie. 2003. PMID: 14605460 Review.
[Advances in the treatment of ovarian carcinoma].
Pfisterer J, du Bois A, Hilpert F, Wagner U, Meier W. Pfisterer J, et al. Among authors: hilpert f. Dtsch Med Wochenschr. 2004 Feb 20;129(8):379-84. doi: 10.1055/s-2004-819897. Dtsch Med Wochenschr. 2004. PMID: 14961446 Review. German. No abstract available.
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D, Hilpert F; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group. Pfisterer J, et al. Among authors: hilpert f. Gynecol Oncol. 2004 Mar;92(3):949-56. doi: 10.1016/j.ygyno.2003.12.004. Gynecol Oncol. 2004. PMID: 14984965 Clinical Trial.
Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.
Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B, du Bois A; Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Hilpert F, et al. Support Care Cancer. 2005 Oct;13(10):797-805. doi: 10.1007/s00520-005-0782-y. Epub 2005 Jul 16. Support Care Cancer. 2005. PMID: 16025262 Clinical Trial.
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Greimel ER, et al. Among authors: hilpert f. J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067. J Clin Oncol. 2006. PMID: 16446330 Clinical Trial.
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: hilpert f. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66. doi: 10.1158/1078-0432.CCR-06-0691. Clin Cancer Res. 2007. PMID: 17255266
160 results